Forge Life Science Partners
VC Fund
Forge Life Science Partners is an investment firm.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Forge Life Science Partners invests in
Stages Forge Life Science Partners invests in
Countries Forge Life Science Partners invests in
Investment Focus
Industry
- Biotechnology 5 (63%)
- Therapeutics 3 (38%)
- Pharmaceutical 3 (38%)
- Health Care 2 (25%)
- Product Research 2 (25%)
Stage
- Series A 2 (25%)
- Series B 2 (25%)
- Post-IPO Equity 2 (25%)
- Series C 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kinaset Therapeutics
|
Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M / Series B / Jan 10, 2026 | |
|
Kinaset Therapeutics
|
Kinaset Therapeutics is a therapeutics company that focuses on the advancement of novel drugs in areas of unmet medical needs. The company was founded in 2020 and is headquartered in Medfield, Massachusetts. | $103M / Series B / Jan 10, 2026 | |
SAB Biotherapeutics
|
A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems,rare conditions, long-term diseases and global pandemic threats. | $175M / Post-IPO Equity / Jul 21, 2025 | |
Aclaris Therapeutics
|
Aclaris Therapeutics started by the founders of Vicept Therapeutics, is a privately held specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies. It is committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both medical andaesthetic, and immunology. Aclaris is focused on market segments with no FDA-approved medications or where treatment gaps exist. | $80M / Post-IPO Equity / Nov 18, 2024 | |
Idrx
|
IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. | $120M / Series B / Aug 07, 2024 | |
OnCusp Therapeutics
|
OnCusp Therapeutics is a biopharmaceutical company turning cutting-edge research assets into innovative oncology treatments.It is always working to improve the largest value inflection point in the drug development value chain, believing that speeding oncology medication innovation is the most effective method to provide help and hope to cancerpatients around the world.It is founded by Bing Yuan, Eric Slosberg, and Andy Fu. | $100M / Series A / Jan 04, 2024 | |
Escient Pharmaceuticals
|
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases, enabling its clients to receive drugs required fortreatment of serious, unserved medical needs across a broad range of therapeutic indications. | $120M / Series C / Nov 28, 2022 | |
|
Idrx
|
IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. | $122M / Series A / Aug 02, 2022 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Forge Life Science Partners invest in?
Forge Life Science Partners invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Forge Life Science Partners last invest?
The most recent investment recorded for Forge Life Science Partners closed in Jan 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
